A Phase 3 interventional study of methotrexate and rituximab [MabThera/Rituxan] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 97 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-11-03.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 13th largest by enrollment, is the only one that started in 2004, is one of 27 in phase 3, and was the 48th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 27 · Phase 4 14
First in 2001; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 341 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 159 across the 63 interventional studies. Of the 57 that completed or were terminated, 37 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 37th largest by enrollment of the 141 interventional ones that give a count, is one of 5 that started in 2004, is one of 85 in phase 3, and was the 187th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the long-term safety and efficacy of repeating treatment with MabThera, in combination with methotrexate and steroids, in patients who were previously randomized into MabThera study WA17042. The anticipated time on study treatment is until Mabthera is available on the local market and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: methotrexate · Drug: rituximab [MabThera/Rituxan]
a 10-25 mg stable dose given orally or parenterally throughout study
Drug page: Rituximab
1 g given by intravenous infusion on Days 1 and 15 of each treatment course
Also known as: MabThera/Rituxan
Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response
A patient had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity \[symptom-free and no arthritis symptoms\], right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain and right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate). The ACR20 response was compared to Baseline in the precursor study WA17042. The first retreatment may have occurred in the precursor study WA17042.
Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)
Change From Baseline in the Disease Activity Score 28 (DAS28)
The DAS28 is an index for measuring disease activity in rheumatic arthritis and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where a higher score represents higher disease activity. A negative change score indicates improvement. The first retreatment may have occurred in the precursor study WA17042.
Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)
Percentage of Participants With DAS28 Low Disease Activity and DAS28 Remission
The DAS28 is an index for measuring disease activity in rheumatic arthritis and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Low disease activity was defined as a DAS28 score ≤ 3.2. DAS28 remission was defined as a DAS28 score \< 2.6. The first retreatment may have occurred in the precursor study WA17042.
Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)
Percentage of Participants With Good, Moderate, or no European League Against Rheumatism (EULAR) Responses
Change of the Disease Activity Score 28 score from baseline was used to determine EULAR responses of good, moderate, or no response. For a post-baseline score ≤ 3.2, a change from baseline of \< -1.2 was a good response, \< -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-baseline score \> 3.2 to ≤ 5.1, a change from baseline of \< -0.6 was a moderate response and ≥ -0.6 was no response. For a post-baseline score \> 5.1, a change from baseline \< -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-baseline scores \> 3.2. The first retreatment may have occurred in the precursor study WA17042.
Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)
Change From Baseline in the American College of Rheumatology n (ACRn) Response
The ACRn response was defined as each participant's least favorable percentage change from Baseline in 3 measures, tender joint count, swollen joint count (28 assessed joints), and improvement score achieved in at least 3 of the 5 remaining ACR parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity, right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain, right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate). A higher change percentage indicates greater improvement from Baseline. The ACRn response was compared to Baseline in the precursor study WA17042. The first retreatment may have occurred in the precursor study WA17042.
Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)
Change From Baseline in the Physical and Mental Component Scores of the Short Form 36 (SF-36) Health Survey
The SF-36 Health Survey uses patient-reported symptoms on 8 subscales to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100 with a higher score indicating better HRQoL. A positive change score indicates an improvement in HRQoL.
Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)
Change From Baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score
The FACIT-F is a 13-item participant self-reporting questionnaire that assesses fatigue over the previous 7 days by scoring each item on a 5-point scale (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). An overall FACIT-F score was obtained by summing the scores of all 13 items. The overall score ranged from 0 to 52. A lower score indicates less fatigue. A negative change score indicates improvement.
Time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)
Percentage of Participants With no Radiographic Progression From Baseline to Year 5
Radiographic progression was defined as a change of ≤ 0 in the total Genant-modified Sharp score. The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage. Data is reported for 2 groups.
Time frame: Baseline to Year 5
Change From Baseline in the Total Genant-modified Sharp Score at Year 5
The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.
Time frame: Baseline to Year 5
Change From Baseline in the Genant-modified Sharp Erosion Score at Year 5
The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140 which is normalized to 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.
Time frame: Baseline to Year 5
Change From Baseline in the Genant-modified Sharp Joint Space Narrowing Score at Year 5
The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score joint space narrowing of 0-4 (9 gradations) is assigned to 13 joints in each hand and 6 joints in each foot. The maximum joint space narrowing score is 38 x 4.0 = 152 which is normalized to a score of 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.
Time frame: Baseline to Year 5
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Year 5
The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement. Data is reported for 2 groups.
Time frame: Baseline to Year 5
| Milestone | Rituximab |
|---|---|
| Started | 335 |
| Completed | 157 |
| Not completed | 178 |
| Withdrew: Adverse event | 25 |
| Withdrew: Death | 16 |
| Withdrew: Failure to return | 14 |
| Withdrew: Administrative/other | 27 |
| Withdrew: Reason not specified | 96 |
A patient had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity \[symptom-free and no arthritis symptoms\], right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain and right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate). The ACR20 response was compared to Baseline in the precursor study WA17042. The first retreatment may have occurred in the precursor study WA17042.
| Percentage of participants | Rituximab |
|---|---|
| Retreatment 1 (n = 320) | 67.5 |
| Retreatment 2 (n = 267) | 74.9 |
| Retreatment 3 (n = 234) | 73.9 |
| Retreatment 4 (n = 175) | 67.4 |
| Retreatment 5 (n = 136) | 69.9 |
| Retreatment 6 (n = 92) | 72.8 |
The DAS28 is an index for measuring disease activity in rheumatic arthritis and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where a higher score represents higher disease activity. A negative change score indicates improvement. The first retreatment may have occurred in the precursor study WA17042.
| Units on a scale | Rituximab |
|---|---|
| Retreatment 1 (n = 304) | -2.32 ± 1.336 |
| Retreatment 2 (n = 258) | -2.77 ± 1.302 |
| Retreatment 3 (n = 227) | -3.01 ± 1.388 |
| Retreatment 4 (n = 168) | -3.05 ± 1.537 |
| Retreatment 5 (n = 132) | -3.15 ± 1.536 |
| Retreatment 6 (n = 87) | -2.96 ± 1.540 |
The DAS28 is an index for measuring disease activity in rheumatic arthritis and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Low disease activity was defined as a DAS28 score ≤ 3.2. DAS28 remission was defined as a DAS28 score \< 2.6. The first retreatment may have occurred in the precursor study WA17042.
| Percentage of participants | Rituximab |
|---|---|
| Retreatment 1: Low Disease Activity (n=314) | 17.2 |
| Retreatment 1: Remission | 8.9 |
| Retreatment 2: Low Disease Activity (n=265) | 27.9 |
| Retreatment 2: Remission | 15.1 |
| Retreatment 3: Low Disease Activity (n=234) | 36.8 |
| Retreatment 3: Remission | 18.8 |
| Retreatment 4: Low Disease Activity (n=172) | 33.7 |
| Retreatment 4: Remission | 20.9 |
| Retreatment 5: Low Disease Activity (n=135) | 36.3 |
| Retreatment 5: Remission | 20.0 |
| Retreatment 6: Low Disease Activity (n=90) | 33.3 |
| Retreatment 6: Remission | 15.6 |
Change of the Disease Activity Score 28 score from baseline was used to determine EULAR responses of good, moderate, or no response. For a post-baseline score ≤ 3.2, a change from baseline of \< -1.2 was a good response, \< -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-baseline score \> 3.2 to ≤ 5.1, a change from baseline of \< -0.6 was a moderate response and ≥ -0.6 was no response. For a post-baseline score \> 5.1, a change from baseline \< -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-baseline scores \> 3.2. The first retreatment may have occurred in the precursor study WA17042.
| Percentage of participants | Rituximab |
|---|---|
| Retreatment 1: Good Response (n = 304) | 17.1 |
| Retreatment 1: Moderate Response | 64.8 |
| Retreatment 1: No Response | 18.1 |
| Retreatment 2: Good Response (n = 258) | 27.5 |
| Retreatment 2: Moderate Response | 64.3 |
| Retreatment 2: No Response | 8.1 |
| Retreatment 3: Good Response (n = 227) | 36.6 |
| Retreatment 3: Moderate Response | 53.3 |
| Retreatment 3: No Response | 10.1 |
| Retreatment 4: Good Response (n = 168) | 33.9 |
| Retreatment 4: Moderate Response | 58.9 |
| Retreatment 4: No Response | 7.1 |
| Retreatment 5: Good Response (n = 132) | 36.4 |
| Retreatment 5: Moderate Response | 54.5 |
| Retreatment 5: No Response | 9.1 |
| Retreatment 6: Good Response (n = 87) | 33.3 |
| Retreatment 6: Moderate Response | 59.8 |
| Retreatment 6: No Response | 6.9 |
The ACRn response was defined as each participant's least favorable percentage change from Baseline in 3 measures, tender joint count, swollen joint count (28 assessed joints), and improvement score achieved in at least 3 of the 5 remaining ACR parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity, right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain, right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate). A higher change percentage indicates greater improvement from Baseline. The ACRn response was compared to Baseline in the precursor study WA17042. The first retreatment may have occurred in the precursor study WA17042.
| Percentage change | Rituximab |
|---|---|
| Retreatment 1 (n = 320) | 32.04 ± 37.709 |
| Retreatment 2 (n = 267) | 39.25 ± 35.494 |
| Retreatment 3 (n = 234) | 39.89 ± 41.166 |
| Retreatment 4 (n = 175) | 37.71 ± 43.201 |
| Retreatment 5 (n = 136) | 37.59 ± 41.109 |
| Retreatment 6 (n = 92) | 35.53 ± 38.650 |
The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
| Units on a scale | Rituximab |
|---|---|
| Retreatment 1 (n = 320) | -0.51 ± 0.569 |
| Retreatment 2 (n = 267) | -0.54 ± 0.569 |
| Retreatment 3 (n = 234) | -0.56 ± 0.601 |
| Retreatment 4 (n = 175) | -0.55 ± 0.603 |
| Retreatment 5 (n = 136) | -0.60 ± 0.647 |
| Retreatment 6 (n = 92) | -0.55 ± 0.653 |
The SF-36 Health Survey uses patient-reported symptoms on 8 subscales to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100 with a higher score indicating better HRQoL. A positive change score indicates an improvement in HRQoL.
| Units on a scale | Rituximab |
|---|---|
| Retreatment 1: Physical Health (n = 249) | 7.383 ± 8.4618 |
| Retreatment 1: Mental Health | 5.550 ± 12.0705 |
| Retreatment 2: Physical Health (n = 255) | 6.018 ± 7.9757 |
| Retreatment 2: Mental Health | 5.746 ± 10.7778 |
| Retreatment 3: Physical Health (n = 220) | 6.206 ± 8.2326 |
| Retreatment 3: Mental Health | 4.777 ± 10.1916 |
| Retreatment 4: Physical Health (n = 167) | 5.660 ± 7.9137 |
| Retreatment 4: Mental Health | 4.864 ± 10.2215 |
| Retreatment 5: Physical Health (n = 124) | 5.038 ± 8.2643 |
| Retreatment 5: Mental Health | 5.141 ± 11.8848 |
| Retreatment 6: Physical Health (n = 88) | 5.214 ± 7.5370 |
| Retreatment 6: Mental Health | 2.658 ± 9.8556 |
The FACIT-F is a 13-item participant self-reporting questionnaire that assesses fatigue over the previous 7 days by scoring each item on a 5-point scale (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). An overall FACIT-F score was obtained by summing the scores of all 13 items. The overall score ranged from 0 to 52. A lower score indicates less fatigue. A negative change score indicates improvement.
| Units on a scale | Rituximab |
|---|---|
| Retreatment 1 (n = 321) | 10.790 ± 10.7934 |
| Retreatment 2 (n = 272) | 6.390 ± 9.1312 |
| Retreatment 3 (n = 232) | 7.075 ± 9.8208 |
| Retreatment 4 (n = 176) | 6.770 ± 10.4043 |
| Retreatment 5 (n = 131) | 8.030 ± 10.4571 |
| Retreatment 6 (n = 89) | 5.429 ± 9.4251 |
Radiographic progression was defined as a change of ≤ 0 in the total Genant-modified Sharp score. The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage. Data is reported for 2 groups.
| Percentage of participants | Placebo | Rituximab |
|---|---|---|
| Percentage of Participants With no Radiographic Progression From Baseline to Year 5 | 21.5 (12.0 to 31.0) | 32.4 (23.0 to 41.0) |
The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.
| Units on a scale | Placebo | Rituximab |
|---|---|---|
| Change From Baseline in the Total Genant-modified Sharp Score at Year 5 | 5.446 ± 8.4701 | 3.202 ± 6.5538 |
The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140 which is normalized to 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.
| Units on a scale | Placebo | Rituximab |
|---|---|---|
| Change From Baseline in the Genant-modified Sharp Erosion Score at Year 5 | 3.101 ± 4.8980 | 1.880 ± 4.4491 |
The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score joint space narrowing of 0-4 (9 gradations) is assigned to 13 joints in each hand and 6 joints in each foot. The maximum joint space narrowing score is 38 x 4.0 = 152 which is normalized to a score of 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.
| Units on a scale | Placebo | Rituximab |
|---|---|---|
| Change From Baseline in the Genant-modified Sharp Joint Space Narrowing Score at Year 5 | 2.344 ± 4.3263 | 1.322 ± 2.7831 |
The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement. Data is reported for 2 groups.
| Units on a scale | Placebo | Rituximab |
|---|---|---|
| Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Year 5 | -0.408 ± 0.5348 | -0.540 ± 0.6521 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 14/140 (10%) | 112/140 (80%) |
| Rituximab | — | 197/335 (58.8%) | 327/335 (97.6%) |
| Event | Placebo | Rituximab |
|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 1/140 | 23/335 |
| FallInjury, poisoning and procedural complications | 3/140 | 13/335 |
| PneumoniaInfections and infestations | 0/140 | 10/335 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/140 | 10/335 |
| CellulitisInfections and infestations | 0/140 | 6/335 |
| Coronary artery diseaseCardiac disorders | 0/140 | 5/335 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/140 | 5/335 |
| Infusion related reactionGeneral disorders | 0/140 | 5/335 |
| GastroenteritisInfections and infestations | 0/140 | 4/335 |
| PyelonephritisInfections and infestations | 0/140 | 4/335 |
| Event | Placebo | Rituximab |
|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 57/140 | 217/335 |
| Infusion related reactionGeneral disorders | 26/140 | 155/335 |
| Upper respiratory tract infectionInfections and infestations | 14/140 | 132/335 |
| NasopharyngitisInfections and infestations | 12/140 | 101/335 |
| Urinary tract infectionInfections and infestations | 11/140 | 86/335 |
| BronchitisInfections and infestations | 9/140 | 81/335 |
| FallInjury, poisoning and procedural complications | 4/140 | 71/335 |
| SinusitisInfections and infestations | 13/140 | 68/335 |
| Back painMusculoskeletal and connective tissue disorders | 6/140 | 68/335 |
| HeadacheNervous system disorders | 7/140 | 61/335 |
Safety population: All participants who received any part of an infusion of study medication.
| Age, Continuous(years) | Rituximab |
|---|---|
| Mean | 53.1 ± 11.81 |
| Sex: Female, Male(Participants) | Rituximab |
|---|---|
| Female | 273 |
| Male | 62 |
The record gives a start of Jun 2004, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab